Differential effects of various typical and atypical antipsychotics on plasma glucose and insulin levels in the mouse: evidence for the involvement of sympathetic regulation.
Atypical antipsychotic treatment has been associated with serious metabolic adverse events, such as glucose dysregulation and development of type 2 diabetes. As part of our studies on possible underlying mechanisms, we investigated the acute effects of various typical and atypical antipsychotics on plasma glucose and insulin in FVB/N mice, a strain that showed a more pronounced hyperglycemic response to clozapine than C57BL/6 and CD-1 mice. Acute administration of high doses of clozapine, olanzapine, quetiapine, perphenazine, or chlorpromazine significantly increased plasma glucose by 100%-140% above basal levels without significant effects on insulin levels. In contrast, risperidone reduced plasma glucose (-30%) and markedly enhanced plasma insulin levels. Doses of ziprasidone that gave 50-fold higher free plasma concentrations than therapeutic plasma levels, as well as high doses of aripiprazole and haloperidol, did not significantly alter either glucose or insulin levels. Clozapine- and olanzapine-induced hyperglycemia occurred at free plasma concentrations that were within, or one order of magnitude above, the range of therapeutic plasma levels. Pretreatment with either the ganglionic blocker hexamethonium, or the alpha(2) adrenergic receptor antagonist yohimbine, blocked the clozapine- and chlorpromazine-induced increase in glucose levels. Taken together, these results suggest that typical and atypical antipsychotics with known metabolic liability produce acute hyperglycemia in mice and that this effect is likely driven by activation of the sympathetic autonomic nervous system via a central mechanism.
Savoy
Yvette E
YE
Department of General Pharmacology, Pfizer Global Research and Development,Pfizer Inc, Groton, CT 06340, USA.
Ashton
Michael A
MA
Miller
Matthew W
MW
Nedza
Frank M
FM
Spracklin
Douglas K
DK
Hawthorn
Mark H
MH
Rollema
Hans
H
Matos
F Fatima
FF
Hajos-Korcsok
Eva
E
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D014150:Antipsychotic Agents / Q000633:toxicity*; D001786:Blood Glucose / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D005730:Ganglionic Blockers / Q000494:pharmacology; D005951:Glucose Tolerance Test; D018738:Hexamethonium / Q000494:pharmacology; D006706:Homeostasis / Q000187:drug effects; D006943:Hyperglycemia / Q000139:chemically induced* / Q000503:physiopathology; D007328:Insulin / Q000097:blood*; D008297:Male; D051379:Mice; D013564:Sympathetic Nervous System / Q000187:drug effects* / Q000503:physiopathology; D015016:Yohimbine / Q000494:pharmacology
D000317:Adrenergic alpha-Antagonists; D014150:Antipsychotic Agents; D001786:Blood Glucose; D005730:Ganglionic Blockers; D007328:Insulin; D015016:Yohimbine; D018738:Hexamethonium